a Phase 2 clinical trial in WHO Group I PAH patients with an oral formulation of a novel endogenous compound as a disease modifying therapy

Brief description of study

This study is being done to see whether a new study drug, called CXA-10, can help lower the pressure in the blood vessels from the heart to the lungs in people with pulmonary arterial hypertension (PAH), can help improve heart health, and to see if it is safe. PAH is high blood pressure in the blood vessels that go from the heart to the lungs. It is harder for blood to flow through these vessels because they have become narrow. This causes the heart to work harder and can lead to a weakening of the heart. CXA-10 is a natural substance that is normally found in the body in low levels. Based on earlier studies, it is believed that CXA-10 works by reducing inflammation in the body. Inflammation is the body's attempt to heal itself after an injury, but it can also play a role in some diseases. Inflammation is one of the processes involved in PAH. As CXA-10 may be able to reduce inflammation and researchers think CXA-10 may be able to improve pressure in the blood vessels from the heart to the lungs and how the heart works. The study will also look at two different doses of CXA-10 and if there is any difference in how well they work and their safety. CXA-10 is an experimental drug. This means it has not been approved by the US Food and Drug Administration. The pharmaceutical company sponsoring this study is Complexa, Inc.

Clinical Study Identifier: s17-01737
ClinicalTrials.gov Identifier: NCT03449524

If you are registered as a volunteer, please login to the dashboard to send referrals.